Shanghai Sunstem Biotechnology

Shanghai Sunstem Biotechnology is a clinical-stage biotechnology company specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. Based in Shanghai, the company leverages a proprietary platform for the large-scale, standardized production of high-purity functional cells for regenerative medicine. Its primary focus areas include neurodegenerative diseases, ophthalmology, and cardiology, with a lead program targeting Parkinson's disease through dopaminergic neuron replacement. Sunstem's lead candidate, SSW-001, has received IND clearance and entered clinical evaluation, marking a significant milestone in its pipeline. The company is supported by prominent venture capital firms and aims to provide off-the-shelf cell therapy solutions for global markets.